계명대학교 의학도서관 Repository

고콜레스테롤혈증 환자에 대한 아토바스타틴의 효과와 안전성을 검토하기 위한 다기관 공동 임상 연구

Metadata Downloads
Author(s)
전재은박의현김권배김기식이재우이원로박정의최윤식권영주강정채김종준문용홍순표김태호김영조심봉섭박승정정진원이건주최규보임종윤이방헌
Keimyung Author(s)
Kim, Kwon BaeKim, Kee Sik
Department
Dept. of Internal Medicine (내과학)
Journal Title
순환기
Issued Date
2001
Volume
31
Issue
4
Keyword
AtorvastatinHypercholesterolemiaMulticenter clinical
Abstract
Background & Objectives:The aim of this study was to investigate the efficacy & safety of a new HMGCoA
reductase inhibitor, atorvastatin, to improve serum lipid profiles in patients with primary hypercholesterolemia.
Materials & Methods:Three hundred and six patients from 21 hospitals, all with total cholesterol
level over 240 mg/dl and triglyceride level below 400 mg/dl were enrolled in the study. Following diet therapy
for 2 weeks, atorvastatin 10 mg was taken for 6 weeks if the total cholesterol level remained higher than 240
mg/dl. The percent change of total cholesterol, triglyceride, LDL-cholesterol and HDL-cholesterol from baseline to 6 weeks of treatment were evaluated. Patients were monitored for safety through careful history talking,
physical examination, serum sampling for liver and muscle enzyme. Results:1) The study was completed in
a total of 166 patients. The mean age of patients the was 58 1/2 years and the percent of male and female
patients was 37%, 37% and 63%, respectively. 2) The baseline mean values of total cholesterol, triglyceride,
LDL-cholesterol, HDL-cholesterol following diet therapy for 2 weeks were 280±34 mg/dl, 172±77 mg/dl,
190±35 mg/dl, 56±13 mg/dl, respectively. 3) After 6 weeks treatment, the level of total cholesterol, triglyceride,
LDL-cholesterol, HDL-cholesterol were 195±34 mg/d, 150±67 mg/dl, 110±33 mg/dl, 55±12 mg/dl,
respectively, and the rates of change were -30%, -7%, -42%, -0.2%, respectively. 4) The level of LDLcholesterol
at the end of treatment was below 100 mg/dl in 44%, 100-130 mg/dl in 33%, 130-160 mg/dl in
14%, over 160 mg/dl in 9% of patients. 5) 77% of total patients achieved the target goal of LDL cholesterol
(below 130 mg/dl) according to the NCEP guideline. 6) The reduction rate of LDL-cholesterol was different
among the patients. At the end of treatment, the patients with initial LDL-cholesterol below 100 mg/dl
achieved a higher reduction rate (52%) as compared with those patient’s inithal LDL-cholesterol level were
higher. 7) There are was only 1 patient (0.6%) who showed 3 times a three-fold increase of liver enzyme and
no patient showed an increase of creatine kinase. Conclusion:Atorvastatin is effective and safe in improving
the lipid profiles in of patients with hypercholesterolemia without serious side effects. (Korean Circulation J
2001;31(4):434-441)
Alternative Title
Multicenter Clinical Trial of Atorvastatin in Patients with Hypercholesterolemia
Keimyung Author(s)(Kor)
김권배
김기식
Publisher
School of Medicine
Citation
전재은 et al. (2001). 고콜레스테롤혈증 환자에 대한 아토바스타틴의 효과와
안전성을 검토하기 위한 다기관 공동 임상 연구. 순환기, 31(4), 434–441. doi: 10.4070/kcj.2001.31.4.434
Type
Article
ISSN
1225-164X
DOI
10.4070/kcj.2001.31.4.434
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/36745
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.